Medicine
Pristiq Extended-Release 100 mg extended-release tablet
Pristiq Extended-Release 100 mg extended-release tablet is a prescription medicine containing Desvenlafaxine for oral use, marketed by Wyeth Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59°…
Key facts
- Active ingredient (INN)
- Desvenlafaxine
- Brand
- Pristiq Extended-Release
- Strength
- 100 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 90 tablets, 14 tablets, 30 tablets and 1 more
- Marketing authorisation holder
- Wyeth Pharmaceuticals
- Manufacturer
- Wyeth Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N06AX23 Desvenlafaxine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 May 2008
- Identifiers
- RxCUI 790267, 790290, 1607617 +3DailyMed set ID 0f43610c-f290-46ea-d186-4f998ed99fceNDC 0008-1222Application NDA021992
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 90 tablet, extended release in 1 bottle, plastic | 0008-1222-01 | Wyeth Pharmaceuticals | 1 May 2008 |
| 14 tablet, extended release in 1 bottle, plastic | 0008-1222-14 | Wyeth Pharmaceuticals | 1 May 2008 |
| 30 tablet, extended release in 1 bottle, plastic | 0008-1222-30 | Wyeth Pharmaceuticals | 1 May 2008 |
| 100 blister pack in 1 carton / 1 tablet, extended release in 1 blister pack | 0008-1222-50 | Wyeth Pharmaceuticals | 1 May 2008 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Desvenlafaxine 100 mg extended-release tablet.
Other strengths and forms of Desvenlafaxine
Clinical summary
Desvenlafaxine is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of adults with major depressive disorder (MDD). It is available as extended-release tablets for oral use. MedsAcross supplies Desvenlafaxine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DesvenlafaxineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Pristiq Extended-Release prescribing information (Wyeth Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Pristiq Extended-Release 100 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.